about
sameAs
Lost in translation: pluripotent stem cell-derived hematopoiesisGranulocyte colony-stimulating factor (G-CSF) treatment of childhood acute myeloid leukemias that overexpress the differentiation-defective G-CSF receptor isoform IV is associated with a higher incidence of relapseTreatment and prognostic impact of transient leukemia in neonates with Down syndromemiR-125b-2 is a potential oncomiR on human chromosome 21 in megakaryoblastic leukemia.GATA1s induces hyperproliferation of eosinophil precursors in Down syndrome transient leukemia.Classification of pediatric acute myeloid leukemia based on miRNA expression profiles.LincRNAs MONC and MIR100HG act as oncogenes in acute megakaryoblastic leukemia.Developmental stage-specific interplay of GATA1 and IGF signaling in fetal megakaryopoiesis and leukemogenesisThe role of matched sibling donor allogeneic stem cell transplantation in pediatric high-risk acute myeloid leukemia: results from the AML-BFM 98 study.Improved outcome of pediatric patients with acute megakaryoblastic leukemia in the AML-BFM 04 trial.MicroRNA-106b~25 cluster is upregulated in relapsed MLL-rearranged pediatric acute myeloid leukemia.Histone deacetylase inhibitors induce apoptosis in myeloid leukemia by suppressing autophagymiR-99a/100~125b tricistrons regulate hematopoietic stem and progenitor cell homeostasis by shifting the balance between TGFβ and Wnt signaling.Prospects and challenges of reprogrammed cells in hematology and oncology.A four-gene LincRNA expression signature predicts risk in multiple cohorts of acute myeloid leukemia patients.Reduced Erg Dosage Impairs Survival of Hematopoietic Stem and Progenitor Cells.Therapy reduction in patients with Down syndrome and myeloid leukemia: the international ML-DS 2006 trial.miR-139-5p controls translation in myeloid leukemia through EIF4G2.Involvement of p53 in the cytotoxic activity of the NAMPT inhibitor FK866 in myeloid leukemic cells.Inhibition of NAMPT pathway by FK866 activates the function of p53 in HEK293T cells.Next-generation personalised medicine for high-risk paediatric cancer patients - The INFORM pilot study.CRISPR-Cas9-induced t(11;19)/MLL-ENL translocations initiate leukemia in human hematopoietic progenitor cells in vivo.MicroRNA-125b-5p mimic inhibits acute liver failure.The non-coding RNA landscape of human hematopoiesis and leukemia.DNMT3A mutations are rare in childhood acute myeloid leukemia.Low frequency of type-I and type-II aberrations in myeloid leukemia of Down syndrome, underscoring the unique entity of this disease.miRNAs can increase the efficiency of ex vivo platelet generation.[Long non-coding RNAs as central regulators of hematopoiesis and leukemogenesis].Improved generation of patient-specific induced pluripotent stem cells using a chemically-defined and matrigel-based approach.Characterization of oncogenes on chromosome 21 identified by shRNA-based viability screening.Refined sgRNA efficacy prediction improves large- and small-scale CRISPR-Cas9 applications.lncRNA MIR100HG-derived miR-100 and miR-125b mediate cetuximab resistance via Wnt/β-catenin signaling.miR-9 is a tumor suppressor in pediatric AML with t(8;21).Endogenous Tumor Suppressor microRNA-193b: Therapeutic and Prognostic Value in Acute Myeloid Leukemia.Successes and challenges in the treatment of pediatric acute myeloid leukemia: a retrospective analysis of the AML-BFM trials from 1987 to 2012.High frequency of copy number alterations in myeloid leukaemia of Down syndrome.Analysis of GATA1 mutations in Down syndrome transient myeloproliferative disorder and myeloid leukemiaConcomitant aberrant overexpression of RUNX1 and NCAM in regenerating bone marrow of myeloid leukemia of Down's syndromeJanus kinase mutations in the development of acute megakaryoblastic leukemia in children with and without Down's syndromeDevelopmental stage-selective effect of somatically mutated leukemogenic transcription factor GATA1
P50
Q26801840-34A070E7-76F0-4F69-856F-AD0B594B40F8Q28280300-3F0204CE-5DC7-4FBB-B11C-6CBE2DDC0663Q33378192-D3EBF205-DFF9-4B1F-82FD-AF17E3EF7DB4Q33685173-493C8C1B-67FC-4C90-B088-4649FD42BB2CQ33717768-FE253C61-C20A-4B52-B238-A52CAACA691BQ33779361-476B3D66-DE0E-459D-9AE3-8D8717778520Q33986195-5C6A76EB-04B0-4C66-8F6B-DE9E7F1A092FQ34030154-17C92665-F289-4BA1-8C88-D7AA90613256Q35643005-09F9334D-D398-485B-8FE5-155B51F83028Q35807969-BFEAED23-D5BD-4DB6-91E2-9E7376A63489Q37565488-BD9648F2-9611-41D5-B1AF-C857BBBA1CFEQ37626910-E0F3A996-6988-42D7-B5AB-0E585174E6B8Q37729765-CFECCE25-779F-41E2-9135-252A4B85B9A4Q38031618-1505F195-3254-466A-9D9A-06BE180553C5Q38695117-13CEF08C-2B29-4F5A-814F-2253ECC5E9B1Q38823486-DB384934-895E-4BE4-8250-E33D2DE18C7CQ38841562-106AD83C-8CC7-4C86-8F19-8C0590FC1AC8Q38854034-0528BB42-8517-42F6-8722-4E8AE2AA3427Q39311489-12ACFF23-1406-45DE-B154-704DD164F04CQ39326085-0586F28B-A923-436D-BE01-F6D592D70D1BQ39538403-4BBF1940-3D73-4875-8832-75780D02A852Q40188620-E4E5D476-FA96-4B93-9B20-189228338F4FQ40639545-F3BA6AF3-572D-4506-B7C6-AB888D2151A5Q41331438-8F62EAFD-24C9-4D2F-8B62-E5B45A12CB38Q42852417-F08037CF-FA32-4DA7-8DB6-CABE4A671F00Q43166287-6B8410D2-36D0-4139-8169-BBACD61F942AQ44209682-CEC09627-2249-40E5-A070-62D5DA8DE60CQ45001766-F155C4A1-FE0E-48C8-BE5A-A5F34F8F57E9Q45353644-CC7C3E2A-D58C-4F7A-BD9B-D4BEFA06115AQ46732863-BF4B4488-BA2E-44AE-A571-E5FECFA5E3B7Q47572675-03DEA495-D85D-44CD-A985-27CED9BDF963Q47648793-796A044E-E9E5-4270-859C-96052512AAB7Q48336259-39EA1CF5-23B7-44A6-B942-199074A032ABQ50047489-120B159E-59FA-41F6-B438-1A11787C3881Q52725969-0D5486E1-A53F-4836-BCFE-0AFFC72F8BF0Q54498661-1988E814-738E-4697-A025-CEF076BD731CQ64008521-9C320C37-56DF-4FFF-8673-44DE9001B17CQ79249571-0DE95E92-EDFF-4C07-9F54-D429FBA2493CQ80178966-8C23BF31-2FF4-4694-BA61-B35D4A18EF51Q81749163-D46DC5B1-5E43-4B9A-A8CB-16B6F809CFF7
P50
description
hulumtues
@sq
researcher
@en
ricercatore
@it
taighdeoir
@ga
wetenschapper
@nl
հետազոտող
@hy
name
Jan-Henning Klusmann
@ast
Jan-Henning Klusmann
@en
Jan-Henning Klusmann
@es
Jan-Henning Klusmann
@nl
Jan-Henning Klusmann
@sl
type
label
Jan-Henning Klusmann
@ast
Jan-Henning Klusmann
@en
Jan-Henning Klusmann
@es
Jan-Henning Klusmann
@nl
Jan-Henning Klusmann
@sl
prefLabel
Jan-Henning Klusmann
@ast
Jan-Henning Klusmann
@en
Jan-Henning Klusmann
@es
Jan-Henning Klusmann
@nl
Jan-Henning Klusmann
@sl
P108
P214
P227
P1153
16643253200
P19
P21
P213
0000 0000 2294 5671
P214
P227
P31
P496
0000-0002-1070-0727
P569
1979-01-01T00:00:00Z
P7859
viaf-38109427